Novo Nordisk
285.15 DKK
-0.78 %
NOVO B
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.
Read moreRevenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
Interim report Q2'26
Interim report Q3'26
Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke
HCA Morgenbørs 26/05 - Lukkede markeder ser ud til at skulle catche op på mandagens stigninger
Join Inderes community
Don't miss out - create an account and get all the possible benefits



